Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$462.32−3.35 (-0.72%)
Close on Nov 16, 2026Market cap $249.95BP/E 26.8Yield 2.09%
Amgen r&d expenses
Research and development expenses are spending on new products and technology.
Amgen's R&D Expenses for the twelve months ending Sep 30, 2026 was $7.84B, up 14.4% year over year. For fiscal 2025 it was $7.27B, up 21.9% from the year before. Over ten years it grew 6.0% a year on average. The highest annual figure on record is $7.27B in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.27B | +21.9% |
| FY2024 | Dec 31, 2024 | $5.96B | +24.7% |
| FY2023 | Dec 31, 2023 | $4.78B | +7.9% |
| FY2022 | Dec 31, 2022 | $4.43B | -8.0% |
| FY2021 | Dec 31, 2021 | $4.82B | +14.5% |
| FY2020 | Dec 31, 2020 | $4.21B | +2.2% |
| FY2019 | Dec 31, 2019 | $4.12B | +10.1% |
| FY2018 | Dec 31, 2018 | $3.74B | +4.9% |
| FY2017 | Dec 31, 2017 | $3.56B | -7.2% |
| FY2016 | Dec 31, 2016 | $3.84B | -5.7% |
| FY2015 | Dec 31, 2015 | $4.07B | -5.3% |
| FY2014 | Dec 31, 2014 | $4.30B | +5.2% |
| FY2013 | Dec 31, 2013 | $4.08B | +20.8% |
| FY2012 | Dec 31, 2012 | $3.38B | +6.7% |
| FY2011 | Dec 31, 2011 | $3.17B | +9.4% |
| FY2010 | Dec 31, 2010 | $2.89B | +1.0% |
| FY2009 | Dec 31, 2009 | $2.86B | -5.5% |
| FY2008 | Dec 31, 2008 | $3.03B | -7.2% |
| FY2007 | Dec 31, 2007 | $3.27B | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.11B | +11.1% |
| Q2 FY2026 | Jun 30, 2026 | $1.87B | +7.1% |
| Q1 FY2026 | Mar 31, 2026 | $1.72B | +15.7% |
| Q4 FY2025 | Dec 31, 2025 | $2.14B | +24.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.90B | +31.0% |
| Q2 FY2025 | Jun 30, 2025 | $1.74B | +20.5% |
| Q1 FY2025 | Mar 31, 2025 | $1.49B | +10.6% |
| Q4 FY2024 | Dec 31, 2024 | $1.72B | +12.4% |
| Q3 FY2024 | Sep 30, 2024 | $1.45B | +34.4% |
| Q2 FY2024 | Jun 30, 2024 | $1.45B | +30.0% |
| Q1 FY2024 | Mar 31, 2024 | $1.34B | +26.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.53B | +15.9% |
| Q3 FY2023 | Sep 30, 2023 | $1.08B | -3.0% |
| Q2 FY2023 | Jun 30, 2023 | $1.11B | +7.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.06B | +10.3% |
| Q4 FY2022 | Dec 31, 2022 | $1.32B | -1.8% |
| Q3 FY2022 | Sep 30, 2022 | $1.11B | +15.0% |
| Q2 FY2022 | Jun 30, 2022 | $1.04B | -15.5% |
| Q1 FY2022 | Mar 31, 2022 | $959.00M | -9.7% |
| Q4 FY2021 | Dec 31, 2021 | $1.35B | +39.8% |
| Q1 FY2021 | Mar 31, 2021 | $967.00M | +1.6% |
| Q4 FY2020 | Dec 31, 2020 | $1.23B | +33.0% |
| Q3 FY2020 | Sep 30, 2020 | $1.06B | +20.8% |
| Q2 FY2020 | Jun 30, 2020 | $964.00M | -18.4% |
| Q1 FY2020 | Mar 31, 2020 | $952.00M | +2.8% |
| Q2 FY2019 | Jun 30, 2019 | $924.00M | +6.3% |
| Q1 FY2019 | Mar 31, 2019 | $879.00M | +15.7% |
| Q4 FY2018 | Dec 31, 2018 | $1.18B | +13.3% |
| Q3 FY2018 | Sep 30, 2018 | $926.00M | +5.6% |
| Q2 FY2018 | Jun 30, 2018 | $869.00M | -0.5% |
| Q1 FY2018 | Mar 31, 2018 | $760.00M | -1.2% |
| Q4 FY2017 | Dec 31, 2017 | $1.04B | -3.2% |
| Q3 FY2017 | Sep 30, 2017 | $877.00M | -11.4% |
| Q2 FY2017 | Jun 30, 2017 | $873.00M | -3.0% |
| Q1 FY2017 | Mar 31, 2017 | $769.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.08B | – |
| Q3 FY2016 | Sep 30, 2016 | $990.00M | – |
| Q2 FY2016 | Jun 30, 2016 | $900.00M | – |
See a number that looks wrong?